Entering text into the input field will update the search result below

Takeda to acquire Nimbus' potential psoriasis drug for $4B upfront

Dec. 13, 2022 7:53 AM ETTakeda Pharmaceutical Company Limited (TAK) StockBy: Ravikash Bakolia, SA News Editor

Takeda Pharmaceutical Company

hapabapa

Takeda Pharmaceutical (NYSE:TAK) is acquiring Nimbus Therapeutics' Nimbus Lakshmi and its potential psoriasis therapy NDI-034858 for $4B upfront plus two milestone payments of $1B each.

The Japanese drugmaker said NDI-034858 is an oral, selective allosteric TYK2 inhibitor being evaluated to

Recommended For You

More Trending News

About TAK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TAK--
Takeda Pharmaceutical Company Limited